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      Dear  Sir: 
  We appreciate the letter of Montresor and others,  1  and are 
grateful for their level of attention to the data reported from 
this study.  2  Unfortunately, the concerns raised do not accu-
rately reflect our observations, nor are they warranted based 
on the paper’s stated conclusions. 
  The writers point out that cure rate is an inadequate mea-
sure of drug effectiveness because of its dependence on pre-
treatment intensity. However, in our study population, we 
reported that pretreatment intensity did not correlate with 
cure rate. Moreover, nearly all of the hookworm infection 
intensities were light, which should have predicted a better 
response to albendazole. Our data show that this was not the 
case in the study population. 
  The writers also suggest that egg reduction rate is a better 
measure of drug effectiveness than cure rate, a claim we nei-
ther  refute nor promote in the paper. They state that the 
fecal egg reduction rate of 81.5% we report “corresponds to 
the normal range of efficacy of albendazole against this para-
site.” Interest  ingly, however, a recent publication (  PLoS Negl 
Trop Dis   2011;5:e948) co-authored by three of the writers 
(Montresor, Engels, and Albonico) notes that, “… a Fecal Egg 
Count Reduction (based on arithmetic means) of > 95% for 
  Ascaris lumbricoides   and  > 90% for hookworms should be the 
expected minimum in all future surveys, and that therapeutic 
efficacy below this level following a single dose of albendazole 
should be viewed with concern in light of potential drug resis-
tance.” Applying this standard, it would seem that our results 
should raise concern about resistance. 
  The writers fail to comment on what is perhaps the most sig-
nificant finding in our study, namely that among those subjects 
who remained positive following treatment with albendazole, 
there was no statistically significant reduction in fecal egg 
excretion, and nearly half had higher egg counts on follow-
up examination. To address potential mechanisms, we consid-
ered a number of possible explanations, including host factors, 
pretreatment intensity, and inactive drug, none of which were 
supported by the data. In the absence of alternative explana-
tions, we believe that the possibility of resistance should be 
considered, especially in light of the implications for current 
global policies. 
  Finally, it must be understood that we do not claim in the 
paper to have determined that the mechanism underlying 
low cure rates in this population is genetically mediated para-
site resistance. Nor do we render any judgment on the rela-
tive value of cure rate versus egg reduction rate as a means 
of monitoring helminth control programs or informing policy. 
Our colleagues are entitled to their opinion as to how these 
complementary tests should be implemented, as has been 
stated in the recently published commentary noted in their 
letter. Moreover, we wholeheartedly agree that the World 
Health Organization (WHO) should be concerned about 
“unjustified claims of drug resistance,” but only when those 
claims are actually made. Given what has been learned about 
anthelminthic resistance from the veterinary nematode expe-
rience, coupled with the recent commitment of funds to scale 
up administration of albendazole across sub-Saharan Africa, 
we would furthermore advocate at the very least that mecha-
nisms to monitor for resistance should be routinely incorpo-
rated into deworming programs. 
  As for the inference that our conclusions suggest a “poor 
understanding of STH biology and control strategies,” the 
authors of the manuscript stand by our data and its interpre-
tation, which passed rigorous peer review by   The Journal   and 
is informed by decades of work in laboratory and field-based 
research. We welcome future dialogue with colleagues who 
share our commitment to improving global health through 
research on endemic infectious diseases.   
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